Clinical trials
-
Prostate cancer: First line hormone sensitive – JSB462 with abiraterone
Read more: Prostate cancer: First line hormone sensitive – JSB462 with abirateroneA Phase II, randomized, open-label, multi-center study of JSB462 (luxdegalutamide) in combination with abiraterone in adult male patients with metastatic hormone-sensitive prostate cancer (mHSPC)
-
Prostate cancer: HRS-5041 – HRPC
Read more: Prostate cancer: HRS-5041 – HRPCA Phase I, Open-label, Multi-Center, Non-Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects with Metastatic Castration-resistant Prostate Cancer
-
Lung Cancer – 2nd line and beyond: Luca-MERIT-1 BNT-116-01
Read more: Lung Cancer – 2nd line and beyond: Luca-MERIT-1 BNT-116-01LuCa-MERIT-1: First-in-human, open label, Phase I dose confirmation trial evaluating the safety, tolerability, and preliminary efficacy of BNT116 alone and in combinations in patients with advanced non-small cell lung cancer
-
Head and Neck SCC 1st line: HPV16+ PD-L1(+) – AHEAD-MERIT BNT-113-01
Read more: Head and Neck SCC 1st line: HPV16+ PD-L1(+) – AHEAD-MERIT BNT-113-01An open-label Phase II/III randomized trial of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as a first line therapy in patients with unresectable recurrent, or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) which is positive for human papilloma virus 16 (HPV16+) and expresses PD-L1
-
Lung cancer: MTAP deleted with AMG193
Read more: Lung cancer: MTAP deleted with AMG193A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects with Methylthioadenosine Phosphorylase (MTAP)-deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)